Skip to main content

Deutivacaftor / Tezacaftor / Vanzacaftor Dosage

Medically reviewed by Drugs.com. Last updated on Feb 24, 2025.

Applies to the following strengths: 125 mg-50 mg-10 mg; 50 mg-20 mg-4 mg

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Cystic Fibrosis

Vanzacaftor 20 mg-tezacaftor 100 mg-deutivacaftor 250 mg orally once a day

Comments:


Use: For the treatment of cystic fibrosis in patients who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

Usual Pediatric Dose for Cystic Fibrosis

6 TO LESS THAN 12 YEARS:
Weight less than 40 kg:
Vanzacaftor 12 mg-tezacaftor 60 mg-deutivacaftor 150 mg orally once a day

Weight at least 40 kg:
Vanzacaftor 20 mg-tezacaftor 100 mg-deutivacaftor 250 mg orally once a day

12 YEARS AND OLDER:
Vanzacaftor 20 mg-tezacaftor 100 mg-deutivacaftor 250 mg orally once a day

Comments:


Use: For the treatment of cystic fibrosis in patients who have at least one F508del mutation or another responsive mutation in the CFTR gene

Renal Dose Adjustments

Mild to moderate renal dysfunction (Estimated GFR 30 to less than 90 mL/min/1.73 m2): No adjustment recommended
Severe renal dysfunction (Estimated GFR less than 30 mL/min/1.73 m2) or End-stage renal disease: Recommended only if benefits outweigh risks

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh A): No adjustment recommended; liver function tests should be closely monitored.
Moderate liver dysfunction (Child-Pugh B): Use is not recommended unless clearly needed and the benefit outweighs the risk. Liver function tests should be closely monitored.
Severe liver dysfunction (Child-Pugh C): Not recommended

Dose Adjustments

Dosage Modification for Strong or Moderate CYP450 3A Inhibitors:

6 TO LESS THAN 12 YEARS:
Weight Less Than 40 kg:


Weight At Least 40 kg:

12 YEARS AND OLDER:

Precautions

US BOXED WARNING(S):
Drug-Induced Liver Injury and Liver Failure:

Recommendations:

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 6 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Monitoring:

Patient advice:

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.